Rennova Health, Inc. announced that it has entered into a securities purchase agreement with certain existing institutional investors for a private placement of up to 1,650 shares of series P convertible redeemable preferred stock at a price of $909.090909 each share for gross proceeds of $1,500,000 on January 31, 2022. Each share of the series O preferred stock is convertible into shares of the company. The company will receive the funding in two tranches, 1,100 shares in its first tranche and 550 shares in its second tranche.

The shares of series P preferred stock will be issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and by Rule 506 of Regulation D promulgated thereunder.